Skip to Content

Aldeyra Therapeutics Inc ALDX

Morningstar Rating
$3.73 −0.13 (3.37%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALDX is trading within a range we consider fairly valued.
Price
$3.71
Fair Value
$28.60
Uncertainty
Extreme
1-Star Price
$55.35
5-Star Price
$7.29
Economic Moat
Kfvrp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALDX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.86
Day Range
$3.653.88
52-Week Range
$1.4211.97
Bid/Ask
$3.62 / $3.73
Market Cap
$221.62 Mil
Volume/Avg
396,962 / 486,010

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
10

Comparables

Valuation

Metric
ALDX
VRDN
ISEE
Price/Earnings (Normalized)
Price/Book Value
1.952.0711.49
Price/Sales
2,136.72
Price/Cash Flow
Price/Earnings
ALDX
VRDN
ISEE

Financial Strength

Metric
ALDX
VRDN
ISEE
Quick Ratio
6.1423.4715.24
Current Ratio
6.5023.9915.53
Interest Coverage
−17.02−104.84
Quick Ratio
ALDX
VRDN
ISEE

Profitability

Metric
ALDX
VRDN
ISEE
Return on Assets (Normalized)
−17.68%−35.08%−42.04%
Return on Equity (Normalized)
−21.58%−65.95%−50.62%
Return on Invested Capital (Normalized)
−22.95%−42.29%−46.07%
Return on Assets
ALDX
VRDN
ISEE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
PkpgjntrlKqwkk$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
RgjmbmdwXtgmj$114.2 Bil
Moderna Inc
MRNA
PzvshscYwyg$53.7 Bil
argenx SE ADR
ARGX
NbmdkjqrYfwf$23.0 Bil
BioNTech SE ADR
BNTX
ZggrkqdZpbw$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
HgncrhxmvDjhwgf$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
QfnfzndzJxjfcx$15.9 Bil
United Therapeutics Corp
UTHR
RdlxmqpmlLzydr$12.8 Bil
Incyte Corp
INCY
GfrckljzfMqzksl$12.2 Bil
Royalty Pharma PLC Class A
RPRX
VfrlkjjjbgJlngvm$12.2 Bil

Sponsor Center